Srikant M.  Datar net worth and biography

Srikant Datar Biography and Net Worth

Director of Stryker
Dr. Datar is Dean, Harvard Business School and George F. Baker Professor of Business Administration. He was the Arthur Lowes Dickinson Professor at the Graduate School of Business Administration of Harvard University from 1996 to 2020 and is the former Faculty Chair of the Harvard Innovation Labs and Senior Associate Dean for University Affairs. From 1989 to 1996, he was Edmund W. Littlefield Professor at the Graduate School of Business, Stanford University. Dr. Datar is also a director of Novartis AG, a multinational pharmaceutical and consumer health products company, ICF International, Inc., a management, technology and policy consulting firm, and T-Mobile US, Inc., a provider of wireless voice, messaging and data services.

Dr. Datar has an extensive background in accounting and finance and a variety of other business areas, including performance measurement, design thinking and innovation, and machine learning and artificial intelligence. His strong academic and business background and his experience on the board committees of other companies allow him to make significant contributions to our board. His service on the boards of global companies involved in pharmaceuticals and high tech gives him great insights on assessing our technology and strategies to expand our business globally. 

In 2020, Dr. Datar was recognized by the National Association of Corporate Directors (NACD) as the Public Company Director of the Year.

What is Srikant M. Datar's net worth?

The estimated net worth of Srikant M. Datar is at least $1.47 million as of November 29th, 2024. Dr. Datar owns 4,021 shares of Stryker stock worth more than $1,466,057 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Datar may own. Learn More about Srikant M. Datar's net worth.

How do I contact Srikant M. Datar?

The corporate mailing address for Dr. Datar and other Stryker executives is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. Stryker can also be reached via phone at (269) 385-2600 and via email at [email protected]. Learn More on Srikant M. Datar's contact information.

Has Srikant M. Datar been buying or selling shares of Stryker?

Srikant M. Datar has not been actively trading shares of Stryker during the past quarter. Most recently, Srikant M. Datar sold 500 shares of the business's stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $291.92, for a transaction totalling $145,960.00. Following the completion of the sale, the director now directly owns 4,316 shares of the company's stock, valued at $1,259,926.72. Learn More on Srikant M. Datar's trading history.

Who are Stryker's active insiders?

Stryker's insider roster includes Yin Becker (VP), William Berry, Jr. (VP), Glenn Boehnlein (CFO), Srikant Datar (Director), Roch Doliveux (Director), M. Fink (VP), Robert Fletcher (VP), Allan Golston (Director), Kevin Lobo (Chair and CEO), Katherine Owen (VP), James Pierce (Insider), Bijoy Sagar (VP), Timothy Scannell (COO), and Ronda Stryker (Director). Learn More on Stryker's active insiders.

Are insiders buying or selling shares of Stryker?

In the last year, insiders at the medical technology company sold shares 9 times. They sold a total of 489,490 shares worth more than $165,788,442.76. The most recent insider tranaction occured on November, 7th when CEO Kevin Lobo sold 57,313 shares worth more than $21,131,303.10. Insiders at Stryker own 5.9% of the company. Learn More about insider trades at Stryker.

Information on this page was last updated on 11/7/2024.

Srikant M. Datar Insider Trading History at Stryker

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2023Sell500$291.92$145,960.004,316View SEC Filing Icon  
11/14/2023Sell750$287.57$215,677.505,316View SEC Filing Icon  
6/1/2023Sell500$278.50$139,250.005,467View SEC Filing Icon  
5/18/2023Sell1,000$286.00$286,000.005,967View SEC Filing Icon  
12/7/2022Sell1,000$240.25$240,250.006,262View SEC Filing Icon  
12/5/2022Sell500$238.70$119,350.007,262View SEC Filing Icon  
11/7/2022Sell300$212.36$63,708.004,861View SEC Filing Icon  
11/2/2022Sell600$216.71$130,026.005,161View SEC Filing Icon  
11/11/2021Sell1,000$263.12$263,120.00View SEC Filing Icon  
5/19/2020Sell350$191.20$66,920.0017,226View SEC Filing Icon  
5/8/2020Sell200$194.32$38,864.0017,686View SEC Filing Icon  
5/6/2020Sell200$186.01$37,202.0017,686View SEC Filing Icon  
8/15/2019Sell350$215.00$75,250.006,844View SEC Filing Icon  
See Full Table

Srikant M. Datar Buying and Selling Activity at Stryker

This chart shows Srikant M Datar's buying and selling at Stryker by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Stryker Company Overview

Stryker logo
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Read More

Today's Range

Now: $364.60
Low: $356.00
High: $364.80

50 Day Range

MA: $374.66
Low: $352.82
High: $392.15

2 Week Range

Now: $364.60
Low: $288.90
High: $398.20

Volume

3,146,655 shs

Average Volume

1,269,702 shs

Market Capitalization

$138.99 billion

P/E Ratio

39.08

Dividend Yield

0.86%

Beta

0.94